Free Trial
NASDAQ:DVAX

Dynavax Technologies (DVAX) Stock Price, News & Analysis

Dynavax Technologies logo
$13.98 +0.14 (+1.01%)
Closing price 04:00 PM Eastern
Extended Trading
$13.84 -0.15 (-1.04%)
As of 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Dynavax Technologies Stock (NASDAQ:DVAX)

Key Stats

Today's Range
$13.74
$14.01
50-Day Range
$12.39
$14.40
52-Week Range
$9.74
$14.63
Volume
1.54 million shs
Average Volume
2.00 million shs
Market Capitalization
$1.73 billion
P/E Ratio
77.67
Dividend Yield
N/A
Price Target
$21.50
Consensus Rating
Hold

Company Overview

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Remove Ads

Dynavax Technologies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
91st Percentile Overall Score

DVAX MarketRank™: 

Dynavax Technologies scored higher than 91% of companies evaluated by MarketBeat, and ranked 75th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Dynavax Technologies has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Dynavax Technologies has only been the subject of 3 research reports in the past 90 days.

  • Read more about Dynavax Technologies' stock forecast and price target.
  • Earnings Growth

    Earnings for Dynavax Technologies are expected to grow by 53.13% in the coming year, from $0.32 to $0.49 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Dynavax Technologies is 77.67, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.47.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Dynavax Technologies is 77.67, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.55.

  • Price to Book Value per Share Ratio

    Dynavax Technologies has a P/B Ratio of 2.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Dynavax Technologies' valuation and earnings.
  • Percentage of Shares Shorted

    14.85% of the float of Dynavax Technologies has been sold short.
  • Short Interest Ratio / Days to Cover

    Dynavax Technologies has a short interest ratio ("days to cover") of 9.4.
  • Change versus previous month

    Short interest in Dynavax Technologies has recently decreased by 5.49%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Dynavax Technologies does not currently pay a dividend.

  • Dividend Growth

    Dynavax Technologies does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.85% of the float of Dynavax Technologies has been sold short.
  • Short Interest Ratio / Days to Cover

    Dynavax Technologies has a short interest ratio ("days to cover") of 9.4.
  • Change versus previous month

    Short interest in Dynavax Technologies has recently decreased by 5.49%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Dynavax Technologies has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Dynavax Technologies this week, compared to 4 articles on an average week.
  • Search Interest

    Only 2 people have searched for DVAX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Dynavax Technologies to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Dynavax Technologies insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.98% of the stock of Dynavax Technologies is held by insiders.

  • Percentage Held by Institutions

    96.96% of the stock of Dynavax Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Dynavax Technologies' insider trading history.
Receive DVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter.

DVAX Stock News Headlines

Deep Track Capital sends letter to Dynavax Technologies’ board
$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
Dynavax to execute debt refinancing
See More Headlines

DVAX Stock Analysis - Frequently Asked Questions

Dynavax Technologies' stock was trading at $12.77 at the beginning of 2025. Since then, DVAX stock has increased by 9.5% and is now trading at $13.98.
View the best growth stocks for 2025 here
.

Dynavax Technologies Co. (NASDAQ:DVAX) released its quarterly earnings data on Thursday, February, 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting the consensus estimate of $0.05. The biopharmaceutical company had revenue of $72.03 million for the quarter, compared to analysts' expectations of $72.70 million. Dynavax Technologies had a trailing twelve-month return on equity of 4.22% and a net margin of 9.85%.

Top institutional investors of Dynavax Technologies include Deep Track Capital LP (13.53%), Vanguard Group Inc. (6.97%), Chicago Capital LLC (4.09%) and Deerfield Management Company L.P. Series C (3.95%). Insiders that own company stock include Andrew A F Hack, Ryan Spencer, Robert Janssen, Francis Cano, David F Novack and Justin Burgess.
View institutional ownership trends
.

Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dynavax Technologies investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
2/20/2025
Today
3/25/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:DVAX
Employees
350
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$21.50
High Stock Price Target
$31.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+53.8%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
77.67
Forward P/E Ratio
43.69
P/E Growth
N/A
Net Income
$-6,390,000.00
Pretax Margin
9.29%

Debt

Sales & Book Value

Annual Sales
$277.25 million
Price / Cash Flow
N/A
Book Value
$4.81 per share
Price / Book
2.91

Miscellaneous

Free Float
127,538,000
Market Cap
$1.73 billion
Optionable
Optionable
Beta
1.23

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:DVAX) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners